Physician profile
Robert E Reynolds
NPI 1649275827
$14,773.87
in general payments reported to CMS, 2019-2025
88 companies · $3,054 in 2025
The $3,054 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $1,173 · 2021: $1,078 · 2022: $2,132 · 2023: $2,639 · 2024: $3,032 · 2025: $3,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,418 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,417.93 |
| Education | $307.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,123.11 | 2019-2025 | Kisqali, Piqray |
| Merck Sharp & Dohme LLC | $968.78 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $959.91 | 2019-2025 | |
| Janssen Biotech, INC. | $803.15 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $777.65 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Daiichi Sankyo INC. | $718.22 | 2019-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $549.51 | 2019-2025 | |
| Genentech USA, INC. | $459.80 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Abbvie INC. | $433.55 | 2020-2025 | |
| Celgene Corporation | $402.41 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Glaxosmithkline, LLC. | $392.94 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $364.47 | 2019-2025 | Padcev, Xospata, Xtandi |
| Amgen INC. | $360.41 | 2019-2023 | Kyprolis, Blincyto |
| Gilead Sciences, INC. | $327.06 | 2019-2025 | Trodelvy |
| Incyte Corporation | $309.91 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
Show all 88 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.